Kintara Therapeutics, Inc. (KTRA): Price and Financial Metrics


Kintara Therapeutics, Inc. (KTRA): $0.19

0.00 (2.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KTRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KTRA Stock Price Chart Interactive Chart >

Price chart for KTRA

KTRA Price/Volume Stats

Current price $0.19 52-week high $2.85
Prev. close $0.19 52-week low $0.14
Day low $0.18 Volume 2,170,400
Day high $0.20 Avg. volume 1,855,430
50-day MA $0.29 Dividend yield N/A
200-day MA $0.66 Market Cap 12.58M

Kintara Therapeutics, Inc. (KTRA) Company Bio


Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.


KTRA Latest News Stream


Event/Time News Detail
Loading, please wait...

KTRA Latest Social Stream


Loading social stream, please wait...

View Full KTRA Social Stream

Latest KTRA News From Around the Web

Below are the latest news stories about Kintara Therapeutics Inc that investors may wish to consider to help them evaluate KTRA as an investment opportunity.

H.C. Wainwright Thinks Kintara Therapeutics’ Stock is Going to Recover

In a report released today, Michael King from H.C. Wainwright maintained a Buy rating on Kintara Therapeutics (KTRA – Research Report), with a price target of $3.00. The company's shares closed last Monday at $0.45, close to its 52-week low of $0.33. According to TipRanks.com, King is a 4-star analyst with an average return of 11.9% and a 45.0% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Intellia Therapeutics, and Werewolf Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kintara Therapeutics with a $2.83 average price target, representing a 548.8% upside.

Catie Powers on TipRanks | February 15, 2022

KTRA: A Farewell to GBM

By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Second Quarter Fiscal Year 2022 Operational and Financial Results Kintara Therapeutics, Inc. (NASDAQ:KTRA) announced second quarter fiscal year 2022 financial and operational results in a February 12 th press release and concurrently filed its 10-Q with the SEC. Highlights for the second quarter ended December 31, 2021 and

Yahoo | February 14, 2022

Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate Update

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2021 and provided a corporate update.

Yahoo | February 11, 2022

Maxim Group Remains a Buy on Kintara Therapeutics (KTRA)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Kintara Therapeutics (KTRA – Research Report) on February 2 and set a price target of $1.50. The company's shares closed last Friday at $0.45, close to its 52-week low of $0.33. According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Kintara Therapeutics is a Moderate Buy with an average price target of $3.

Catie Powers on TipRanks | February 7, 2022

Kintara Therapeutics to Present at BIO CEO & Investor Conference on February 15, 2022

Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and Chief Executive Officer, Robert E. Hoffman will present a corporate overview at the BIO CEO & Investor Conference, which is being held on February 14 – 17, 2022 at the New York Marriott Marquis in New York City, NY.

Yahoo | February 4, 2022

Read More 'KTRA' Stories Here

KTRA Price Returns

1-mo -37.07%
3-mo -48.65%
6-mo -73.61%
1-year -88.20%
3-year -88.48%
5-year -99.14%
YTD -62.75%
2021 -60.16%
2020 85.59%
2019 -79.71%
2018 -68.81%
2017 -65.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6939 seconds.